Ultrasound: Treatment Planning System Updated for Real-Time Ultrasound-Guided Prostate Cancer Brachytherapy

A new partnership agreement between Siemens Healthcare (Erlangen, Germany) and Varian Medical Systems (Palo Alto, CA, USA) has been established to advance radiation treatment planning and delivery technology.

General Imaging: Prospective Drawbacks Seen in Cost-Cuts for Medical Imaging Scans

A new report revealed that the timespan of the average hospital stay in the United States has risen at the same time as medical imaging use has dropped. It is not yet known if the trends are linked, but these new findings may be significant, because hospital admissions are among the fastest growing and largest healthcare costs.

Nuclear Medicine: Improved possibilities of proton therapy to patient

A new patient-centric proton therapy room has been designed to stimulate patient comfort during proton treatments by allowing patients to selectively add relaxing sound, light, and images to the treatment room environment before they initiate therapy.

General Imaging: New diagnostic displays developed for radiologists

New diagnostic displays developed for radiologists offer three times the resolution of monochrome liquid crystal displays (LCDs), improving visualization for help in critical diagnoses. Sony Electronics’ medical systems division

MRI: MR-Conditional Pacemaker System Approved in Japan

With the use of new magnetic resonance imaging (MRI)-conditional pacing technology, pacemaker patients will have access to full body scanners, without positioning restriction in the MRI scanner.

Radiography: A new agent has been developed to treat radiation exposure.

A new agent that is similar to a naturally occurring molecule found in blueberries and coffee has been developed to treat radiation exposure.

Nuclear Medicine: PET Radiopharmaceutical Receives European Endorsement for Imaging of β-Amyloid Density

A European health agency has recommended marketing authorization for Amyvid (florbetapir 18F) as a diagnostic imaging agent in patients who are being evaluated for Alzheimer’s disease (AD) and other causes of cognitive decline.